No matches
Dermatology

Clinical Utility of Biomarkers in the Management of AD

Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025
Amy Paller
MD, MS
Amy Paller

Related resources

Mast Cells and the Neuroimmune Axis in CSU

Mast Cells and the Neuroimmune Axis in CSU

expert video
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
UCARE 2023: Neuronal Involvement in CSU

UCARE 2023: Neuronal Involvement in CSU

expert video
UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

expert video
UCARE 2023: CSU – The Brazil Perspective

UCARE 2023: CSU – The Brazil Perspective

expert video
Comorbidities and Disease Burden in CSU

Comorbidities and Disease Burden in CSU

expert video
Treatment Goals, Current and Emerging Therapies in CSU

Treatment Goals, Current and Emerging Therapies in CSU

expert video
Guideline and Patient Management in CSU

Guideline and Patient Management in CSU

expert video
The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

expert video
The Role of Chronic Inflammation in the Pathogenesis of CSU

The Role of Chronic Inflammation in the Pathogenesis of CSU

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

expert video
A brief overview of the pathophysiology of PN

A brief overview of the pathophysiology of PN

expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

expert video
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

Podcast
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Podcast
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Podcast
What Could Remission Mean in AD?

What Could Remission Mean in AD?

expert video
The Risks of Associated Systemic and Atopic Comorbidities with AD

The Risks of Associated Systemic and Atopic Comorbidities with AD

expert video
Factors Associated With Development of Atopic Comorbidities in AD

Factors Associated With Development of Atopic Comorbidities in AD

expert video
Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Early Intervention Shape the Course of Atopic Dermatitis?

expert video
Association of Younger Age of Onset With Persistence of AD

Association of Younger Age of Onset With Persistence of AD

expert video
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Skin Dyspigmentation In Prurigo Nodularis (PN)

Skin Dyspigmentation In Prurigo Nodularis (PN)

interactivity
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Type 2 Inflammation in AD Manifestations in Skin and Body

Type 2 Inflammation in AD Manifestations in Skin and Body

expert video
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

expert video
Can early intervention modify the course of AD?

Can early intervention modify the course of AD?

expert video

Learning objectives

  • Provide expert opinion on clinical utility of biomarker assessment in clinical management of AD
Tags
biomarkers
MAT-GLB-2506011 - 2.0 - 10/2025

About this expert

Dermatology

Amy Paller

MD, MS

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

See author’s profile
Amy Paller

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PanamaChange country/region